Real-World Data in Relapsed Refractory Myeloma Patients Treated with Pomalidomide, a Multicenter Turkish Experience

Introduction: Pomalidomide is a potent immunomodulatory drug (imid) with efficacy demonstrated in relapsed refractory multiple myeloma. In a phase 3 study, pomalidomide showed a benefit of PFS and OS over high dose dexamethasone, even in proteasome inhibitor and imid refractory patients. null In our country, Pomalidomide has recently gained approval in relapsed refractory setting in patients who were both refractory to a proteasome inhibitor and...